Amplia Therapeutics secures FDA fast track status for narmafotinib in pancreatic cancer, stock surges

Amplia Therapeutics secures FDA fast track status for narmafotinib in pancreatic cancer, stock surges

Amplia Therapeutics Limited (ASX: ATX) has announced that its Focal Adhesion Kinase (FAK) inhibitor, narmafotinib, has been granted Fast Track Designation by the United States Food and Drug Administration (FDA). This designation, aimed at expediting the development of drugs intended to address unmet medical needs in serious conditions, could provide an advantage in treating advanced […]

Longboard Pharmaceuticals shares see spike as FDA recognizes potential of bexicaserin in Dravet syndrome

Longboard Pharmaceuticals shares see spike as FDA recognizes potential of bexicaserin in Dravet syndrome

Shares of Longboard Pharmaceuticals, Inc. surged on Thursday after the United States Food and Drug Administration (FDA) granted both Rare Pediatric Disease designation and Orphan Drug designation to its investigational drug, bexicaserin, for the treatment of Dravet syndrome. Pre-market trading saw shares rise by 4.2%, reaching $30.53, a continuation of the company’s upward trend over […]

Avanzanite Bioscience secures EC approval for AKANTIOR as first authorised treatment for acanthamoeba keratitis

Avanzanite Bioscience secures EC approval for AKANTIOR as first authorised treatment for acanthamoeba keratitis

The European Commission (EC) has granted marketing authorisation for AKANTIOR (polihexanide), the first and only approved treatment for acanthamoeba keratitis (AK) globally, announced Avanzanite Bioscience B.V., a commercial-stage specialty pharmaceutical company. The approval, which applies to both adults and children aged 12 and over, marks a significant milestone for the treatment of this rare and […]